Jump to content

User:Mr. Ibrahem/Niraparib

From Wikipedia, the free encyclopedia
Mr. Ibrahem/Niraparib
Clinical data
Pronunciation/nɪˈræpərɪb/
nih-RAP-uh-rib
Trade namesZejula
Other namesNiraparib tosylate, MK-4827
AHFS/Drugs.comMonograph
MedlinePlusa617007
License data
Pregnancy
category
  • AU: D
Routes of
administration		By mouth
Drug classPoly ADP-ribose polymerase (PARP) inhibitor[1]
Legal status
Legal status
Pharmacokinetic data
Bioavailability73%
Protein binding83%
MetabolismCarboxylesterases
MetabolitesM1 (carboxylic acid)
Elimination half-life36 hours
Excretion48% urine, 29% feces
Identifiers
  • 2-[4-[(3S)-3-Piperidyl]phenyl]indazole-7-carboxamide
Chemical and physical data
FormulaC19H20N4O
Molar mass320.396 g·mol−1
3D model (JSmol)
Solubility in water0.7–1.1
  • c1cc2cn(nc2c(c1)C(=O)N)c3ccc(cc3)[C@@H]4CCCNC4
  • InChI=1S/C19H20N4O/c20-19(24)17-5-1-3-15-12-23(22-18(15)17)16-8-6-13(7-9-16)14-4-2-10-21-11-14/h1,3,5-9,12,14,21H,2,4,10-11H2,(H2,20,24)/t14-/m1/s1 checkY
  • Key:PCHKPVIQAHNQLW-CQSZACIVSA-N checkY

Niraparib, sold under the brand name Zejula, is a medication used to treat epithelial ovarian, fallopian tube, or primary peritoneal cancer.[1][3] It is typically used after platinum-based chemotherapy.[4] It is taken by by mouth.[3]

Common side effects include nausea, low platelets, tiredness, low red blood cells, constipation, abdominal pain, low white blood cells, trouble sleeping, headache, diarrhea, shortness of breath, high blood pressure, joint pain, and hot flushes.[3] Other side effects may include myelodysplastic syndrome and infertility.[4] Use in pregnancy may harm the baby.[1] It is a poly ADP-ribose polymerase (PARP) inhibitor.[1]

Niraparib was approved for medical use in the United States and Europe in 2017.[3][4] In the United Kingdom 4 weeks of treatment at 200 mg per day costs the NHS about £4,500.[5] This amount in the United States costs about 16,300 USD.[6]

References[edit]

  1. ^ a b c d e f g "Zejula- niraparib capsule". DailyMed. Archived from the original on 24 March 2021. Retrieved 17 January 2021.
  2. ^ "Zejula 100 mg hard capsules - Summary of Product Characteristics (SmPC)". (emc). Archived from the original on 19 January 2021. Retrieved 17 January 2021.
  3. ^ a b c d e f "Zejula EPAR". European Medicines Agency (EMA). Archived from the original on 13 November 2020. Retrieved 17 January 2021. Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  4. ^ a b c "Niraparib Monograph for Professionals". Drugs.com. Archived from the original on 18 January 2021. Retrieved 13 November 2021.
  5. ^ BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 1050. ISBN 978-0857114105.
  6. ^ "Zejula Prices, Coupons & Patient Assistance Programs". Drugs.com. Archived from the original on 26 January 2021. Retrieved 13 November 2021.
Retrieved from "https://en.wikipedia.org/w/index.php?title=User:Mr._Ibrahem/Niraparib&oldid=1211209393"